{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:32:44Z","timestamp":1793248364023,"version":"4.5.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction and importance:<\/jats:title>\n                    <jats:p>Neuromyelitis optica spectrum disorder (NMOSD) is an antibody-mediated central nervous system disorder, typically presenting with optic neuritis (ON) and longitudinally extensive transverse myelitis (LETM). Detection of anti\u2013aquaporin 4 (AQP4) antibodies establishes the diagnosis, even in patients without classic clinical features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation:<\/jats:title>\n                    <jats:p>A 32-year-old female presented with progressive ascending quadriparesis and sensory deficits. Neurological examination revealed significant hypotonia and weakness, more pronounced in the lower limbs. Spinal magnetic resonance imaging showed LETM involving cervical and thoracic segments, correlating with symptoms. AQP4-IgG positivity confirmed the diagnosis of NMOSD. The patient showed no improvement with intravenous methylprednisolone and plasmapheresis. Subsequent early initiation of Rituximab, combined with comprehensive physiotherapy, resulted in significant functional recovery within a follow-up period of 1 year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical discussion:<\/jats:title>\n                    <jats:p>NMOSD variably presents with limited or atypical presentations. Early-stage disease may be easily overlooked, particularly in the absence of classical optical or spinal symptoms. Early recognition followed by timely initiation of pharmacotherapy and prompt escalation to targeted immunotherapy like Rituximab \u2013 which depletes peripheral B cells and reduces pathogenic AQP4-IgG antibody production targeting disease pathophysiology \u2013 can lead to significant neurological improvement. When combined with comprehensive physiotherapy, these interventions support motor recovery, enhance mobility, and improve overall quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Early recognition of NMOSD and timely escalation to Rituximab, especially when first-line therapies fail, can drive meaningful neurological recovery. Coordinated physiotherapy further strengthens functional outcomes, highlighting the importance of an integrated therapeutic approach in severe or refractory disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000005256","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:01:12Z","timestamp":1782126072000},"page":"4655-4662","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Early rituximab and structured rehabilitation drive rapid functional restoration in steroid- and PLEX-refractory NMOSD: a case report"],"prefix":"10.1097","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1386-4444","authenticated-orcid":false,"given":"Pratisma","family":"Wagle","sequence":"first","affiliation":[{"name":"Manipal Teaching Hospital, Pokhara, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5166-0407","authenticated-orcid":false,"given":"Bijay","family":"Bastola","sequence":"additional","affiliation":[{"name":"Emergency Medicine, Pokhara Academy of Health Sciences, Pokhara, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3491-9070","authenticated-orcid":false,"given":"Umesh","family":"Pant","sequence":"additional","affiliation":[{"name":"Manipal Teaching Hospital, Pokhara, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5723-1790","authenticated-orcid":false,"given":"Bishal","family":"Sapkota","sequence":"additional","affiliation":[{"name":"Emergency Medicine, Pokhara Academy of Health Sciences, Pokhara, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"R1-20261029","doi-asserted-by":"crossref","first-page":"173\u201375","DOI":"10.1212\/CPJ.0000000000000586","article-title":"Neuromyelitis optica spectrum disorder with area postrema syndrome","volume":"9","author":"Okada","year":"2019","journal-title":"Neurol Clin Pract"},{"key":"R2-20261029","doi-asserted-by":"crossref","first-page":"1\u201316","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J Neurol"},{"key":"R3-20261029","doi-asserted-by":"crossref","first-page":"1541\u201347","DOI":"10.1111\/head.12246","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development","volume":"53","author":"Gagnier","year":"2013","journal-title":"Headache"},{"key":"R4-20261029","first-page":"100082","article-title":"Transparency in the Reporting of Artificial Intelligence \u2013 the TITAN Guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R5-20261029","doi-asserted-by":"crossref","first-page":"1905\u201315","DOI":"10.1007\/s10072-023-06617-y","article-title":"Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): a systematic review and meta-analysis","volume":"44","author":"Bagherieh","year":"2023","journal-title":"Neurol Sci"},{"key":"R6-20261029","doi-asserted-by":"crossref","first-page":"1039\u201343","DOI":"10.1001\/archneurol.2012.249","article-title":"Effects of age and sex on aquaporin-4 autoimmunity","volume":"69","author":"Quek","year":"2012","journal-title":"Arch Neurol"},{"key":"R8-20261029","doi-asserted-by":"crossref","first-page":"981\u201391","DOI":"10.1111\/cns.13836","article-title":"Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): novel insights into therapeutic possibilities in NMOSD","volume":"28","author":"Shi","year":"2022","journal-title":"CNS Neurosci Ther"},{"key":"R9-20261029","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12883-021-02059-1","article-title":"Neuromyelitis optica spectrum disorders with non opticospinal manifestations as initial symptoms: a long-term observational study","volume":"21","author":"Li","year":"2021","journal-title":"BMC Neurol"},{"key":"R10-20261029","first-page":"47\u201349","article-title":"\u201cNeuromyelitis optica \u2013 sometimes a misnomer","volume":"23","author":"Paromita","year":"2022","journal-title":"JIACM"},{"key":"R11-20261029","doi-asserted-by":"crossref","first-page":"251\u201365","DOI":"10.1111\/cei.13630","article-title":"Magnetic resonance imaging in neuromyelitis optica spectrum disorder","volume":"206","author":"Clarke","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"R12-20261029","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11940-015-0378-x","article-title":"Acute and chronic management of neuromyelitis optica spectrum disorder","volume":"17","author":"Sherman","year":"2015","journal-title":"Curr Treat Options Neurol"},{"key":"R13-20261029","doi-asserted-by":"crossref","first-page":"36\u201342","DOI":"10.3988\/jcn.2013.9.1.36","article-title":"Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating antiaquaporin-4 antibody levels","volume":"9","author":"Kim","year":"2013","journal-title":"J Clin Neurol"},{"key":"R14-20261029","doi-asserted-by":"crossref","first-page":"806\u201317","DOI":"10.1007\/s11481-021-10004-9","article-title":"The role of plasma exchange in the treatment of refractory autoimmune neurological diseases: a narrative review","volume":"16","author":"Jacob","year":"2021","journal-title":"J Neuroimmune Pharmacol"},{"key":"R15-20261029","doi-asserted-by":"crossref","first-page":"102709","DOI":"10.1016\/j.msard.2020.102709","article-title":"Timing of plasma exchange for neuromyelitis optica spectrum disorders: a meta-analysis","volume":"48","author":"Huang","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"R16-20261029","doi-asserted-by":"crossref","first-page":"1374\u201377","DOI":"10.1177\/0961203318760994","article-title":"Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab","volume":"27","author":"Shidahara","year":"2018","journal-title":"Lupus"},{"key":"R17-20261029","doi-asserted-by":"crossref","first-page":"800\u201305","DOI":"10.1136\/jnnp-2022-330714","article-title":"Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum","volume":"94","author":"Park","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R18-20261029","doi-asserted-by":"crossref","first-page":"106160","DOI":"10.1016\/j.msard.2024.106160","article-title":"Early rituximab versus escalating therapy in neuromyelitis optica: a cost and quality of life analysis","volume":"92","author":"Silva","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"R19-20261029","first-page":"20160007","article-title":"Inpatient multidisciplinary rehabilitation intervention outcomes for neuromyelitis optica spectrum disorder: a retrospective observational study","volume":"1","author":"Ikeda","year":"2016","journal-title":"Prog Rehabil Med"},{"key":"R20-20261029","first-page":"3951\u201359","article-title":"Rehabilitation and pharmacotherapy of neuromyelitis optica spectrum disorder: a case report","volume":"9","author":"Wang","year":"2021","journal-title":"World J Clin Cases"},{"key":"R21-20261029","doi-asserted-by":"crossref","first-page":"e17465","DOI":"10.1097\/MD.0000000000017465","article-title":"Rehabilitation of neuromyelitis optica: two CAREcompliant case reports","volume":"98","author":"Kim","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"R22-20261029","doi-asserted-by":"crossref","first-page":"103726","DOI":"10.1016\/j.msard.2022.103726","article-title":"Efficacy and safety of rehabilitation exercise in neuromyelitis optica spectrum disorder during the acute phase: a prospective cohort study","volume":"61","author":"Li","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"R23-20261029","doi-asserted-by":"crossref","first-page":"1352\u201363","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"R24-20261029","doi-asserted-by":"crossref","first-page":"402\u201312","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"R25-20261029","doi-asserted-by":"crossref","first-page":"614\u201325","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"R26-20261029","doi-asserted-by":"crossref","first-page":"60\u201367","DOI":"10.1016\/S1474-4422(20)30392-6","article-title":"New therapies for neuromyelitis optica spectrum disorder","volume":"20","author":"Levy","year":"2021","journal-title":"Lancet Neurol"},{"key":"R27-20261029","doi-asserted-by":"crossref","first-page":"102990","DOI":"10.1016\/j.msard.2021.102990","article-title":"A pilot trial of autologous hematopoietic stem cell transplant in neuromyelitis optic spectrum disorder","volume":"53","author":"Burton","year":"2021","journal-title":"Mult Scler Relat Disord"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:01:13Z","timestamp":1793246473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000005256","relation":{},"ISSN":["2049-0801","2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"},{"value":"2049-0801","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"2025-12-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}